COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02797665
Recruitment Status : Active, not recruiting
First Posted : June 13, 2016
Last Update Posted : July 24, 2018
Information provided by (Responsible Party):
Peking Union Medical College Hospital

Brief Summary:
This study evaluates corticosteroids in the treatment of obstructive jaundice in autoimmune pancreatitis and/or immunoglobulin G4 (IgG4)-related sclerosing cholangitis in adults. Half of participants will receive corticosteroids alone, while the other half will receive corticosteroids with biliary stent at the beginning.

Condition or disease Intervention/treatment Phase
Autoimmune Pancreatitis IgG4-related Sclerosing Cholangitis Obstructive Jaundice Drug: corticosteroids Procedure: biliary stent Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : May 2016
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : August 2019

Arm Intervention/treatment
Active Comparator: Steroids group
The patients will be treated with oral corticosteroids (prednisone 0.6mg/kg/d) alone.
Drug: corticosteroids
prednisone 0.6mg/kg/d

Active Comparator: Stent group
The patients will be treated with oral corticosteroids and biliary stent.
Drug: corticosteroids
prednisone 0.6mg/kg/d

Procedure: biliary stent
placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)

Primary Outcome Measures :
  1. Clinical remission rate of obstructive jaundice [ Time Frame: Day 60 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults greater than 18 years-old;
  • autoimmune pancreatitis and/or IgG4-related sclerosing cholangitis;
  • obstructive jaundice

Exclusion Criteria:

  • malignancies; active infections;
  • pregnancy or breast feeding;
  • standard contraindications to ERCP;
  • unwillingness or inability to consent for the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02797665

Layout table for location information
China, Beijing
Peking Union Medical College Hospital
Beijing, Beijing, China, 100730
Sponsors and Collaborators
Peking Union Medical College Hospital
Layout table for investigator information
Principal Investigator: Aiming Yang, M.D. Peking Union Medical College Hospital

Layout table for additonal information
Responsible Party: Peking Union Medical College Hospital Identifier: NCT02797665    
Other Study ID Numbers: ZS-844
First Posted: June 13, 2016    Key Record Dates
Last Update Posted: July 24, 2018
Last Verified: July 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangitis, Sclerosing
Jaundice, Obstructive
Pancreatic Diseases
Digestive System Diseases
Bile Duct Diseases
Biliary Tract Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms